Terminated PHASE4 INTERVENTIONAL 2-arm NCT01468623

Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated With mFOLFOX6 (PROFUSE)

A Prospective, Randomized, Open-label Trial Comparing OnDose® AUC Optimized 5-FU Based Administration Versus Standard Body Surface Area (BSA) Dosing in Metastatic Colorectal Cancer Patients (mCRC) Treated With mFOLFOX6

Sponsor: Myriad Genetic Laboratories, Inc.

Conditions Colorectal Cancer, Metastatic

Interventions Pharmacokinetic 5-FU dose adjustment using OnDose® assay Standard of care

Updated 7 times since 2017 Last updated: Jul 18, 2023 Started: Sep 30, 2011 Primary completion: Aug 31, 2012 Completion: Aug 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study terminated due to slow enrollment.

Other terminated trials from Myriad Genetic Laboratories, Inc.

More terminations from Myriad Genetic Laboratories, Inc.

This PHASE4 trial investigates Colorectal Cancer, Metastatic and is currently terminated or withdrawn. Myriad Genetic Laboratories, Inc. leads this study, which shows 7 recorded versions since 2011 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE4
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE4
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE4
Aug 2023 — Jul 2024 [monthly]

Terminated PHASE4
Jan 2021 — Aug 2023 [monthly]

Terminated PHASE4

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Terminated PHASE4
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE4

First recorded

Sep 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Myriad Genetic Laboratories, Inc.

Data source: Myriad Genetic Laboratories, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Ann Arbor, United States , Baton Rouge, United States , Bedford, United States , Bend, United States , Birmingham, United States , Canton, United States , Chicago, United States , Columbus, United States , Corona, United States and 48 more locations